Pembrolizumab
Based on 30 publication(s) in Google Scholar
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
For research use only. We do not sell to patients.
- Purity: 99.82%
- CAS No.: 1374853-91-4
- Molecular Weight:145.24 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Pembrolizumab
More- Immunity. 2024 Feb 13;57(2):256-270.e10. [Abstract]
- Cancer Commun (Lond). 2025 Aug;45(8):1010-1037. [Abstract]
- J Nanobiotechnology. 2025 Jun 3;23(1):413. [Abstract]
- Cell Discov. 2025 Oct 7;11(1):81. [Abstract]
- MedComm (2020). 2025 Sep 12;6(9):e70354. [Abstract]
- J Immunother Cancer. 2024 Aug 6;12(8):e009024. [Abstract]
- J Immunother Cancer. 2022 Mar;10(3):e003667. [Abstract]
- Cell Death Dis. 2025 Jan 21;16(1):34. [Abstract]
- Cell Death Dis. 2021 May 9;12(5):465. [Abstract]
- Mater Des. 2026 Feb 3.
- Cancer Immunol Immunother. 2022 Jul;71(7):1645-1654. [Abstract]
- Cell Oncol (Dordr). 2026 Jan 6;49(1):15. [Abstract]
- Int Immunopharmacol. 2025 Aug 27:164:115406. [Abstract]
- Int J Cancer. 2024 Jul 15;155(2):324-338. [Abstract]
- ACS Appl Bio Mater. 2020 Oct 19;3(10):7080-7086. [Abstract]
- J Biomed Inform. 2023 Jun:142:104383. [Abstract]
- Sci Rep. 2025 Jul 12;15(1):25283. [Abstract]
- Biotechnol Bioeng. 2025 Nov 10. [Abstract]
- Immunol Res. 2024 Aug;72(4):766-775. [Abstract]
- Oral Dis. 2025 Jul 20. [Abstract]
- chemRxiv.
- medRxiv. 2026 Jan 2.
- bioRxiv. 2025 Sep 7.
- Authorea. 2025 May 28.
- Northeastern University. 2025.
- bioRxiv. 2024 September 07.
- bioRxiv. 2024 May 14.
- bioRxiv. 2023 May 12.
- Research Square Print. 2022 Aug.
- Patent. US20200261591A1
-
In Vivo Efficacy Study
-
IF
-
Flow Cytometry
-
In Vivo Efficacy Study
-
IF
Biological Activity
Human IgG4 kappa
Human
PDCD1/PD-1/CD279
Pembrolizumab (MK-3475) increases the secretion of cytokines IFN-γ, TNF-α and the apoptotic cell death of A549 cells[2].
Pembrolizumab improves the αROR1-CAR T-mediated cytotoxicity, and reduces tumorigenesis in the co-cultured αROR1-CAR T and A549 cells by blocking PD-1::PD-L1 interaction in αROR1-CAR T cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:αROR1-CAR T and A549 cells
-
Concentration:10 μg/mL
-
Incubation Time:Adding Pembrolizumab after A549-Red-Fluc cells preconditioned in elevated pressure (+ 100 mmHg) for 7 days.
-
Result:Enhanced αROR1-CAR T killing of A549 lung cancer cells under elevated pressure.
-
Cell Line:A549 cells
-
Concentration:10 μg/mL
-
Incubation Time:
-
Result:Increased the apoptotic cell death in A549 cells, and improve the αROR1-CAR T-mediated cytotoxicity.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Six-week-old male BALB/c athymic nude mice[2]
-
Dosage:5 mg/kg
-
Administration:Pembrolizumab (5 mg/kg; Intravenous injection; Once)
-
Result:Reduced tumorigenesis in αROR1-CAR T cells and co-cultured with A549 cells.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1374853-91-4
-
Appearance Liquid
-
Molecular Weight 145.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Pembrolizumab]
-
Synonyms
MK-3475; Lambrolizumab
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (30)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases. [Abstract]2024 Feb 13;57(2):256-270.e10. PMID: 38354703 -
Cancer Commun (Lond)
Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. [Abstract]2025 Aug;45(8):1010-1037. PMID: 40439109
Pembrolizumab purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Aug;45(8):1010-1037. [Abstract]
Plots of tumor growth and tumor weight for each group (5 mice/group). The results showed that in mice, the combination of Pembrolizumab and Evolocumab significantly enhanced anti-tumor efficacy compared to Pembrolizumab alone (100 µg/mouse; i.p., every 7 days).
-
J Nanobiotechnology
Targeting CD39 boosts PD-1 blockade antitumor therapeutic efficacy via strengthening CD8 + TILs function and recruiting B cells in cervical cancer. [Abstract]2025 Jun 3;23(1):413. PMID: 40462160 -
Cell Discov
Ferroptosis-induced SUMO2 lactylation counteracts ferroptosis by enhancing ACSL4 degradation in lung adenocarcinoma. [Abstract]2025 Oct 7;11(1):81. PMID: 41057295 -
MedComm (2020)
Plasmacytoid and CD141+ Myeloid Dendritic Cells Cooperation with CD8+ T Cells in Lymph Nodes is Associated with HIV Control. [Abstract]2025 Sep 12;6(9):e70354. PMID: 40949488 -
J Immunother Cancer
Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer. [Abstract]2024 Aug 6;12(8):e009024. PMID: 39107132
Pembrolizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Aug 6;12(8):e009024. [Abstract]
The PD-1 expression of macrophages isolated from the subcutaneous tumor microenvironment of mice was detected by flow cytometry (n=5). The results showed that Pembrolizumab (anti-PD-1 Ab) (20 µg/mL, 24 h) reduced PD-1 expression.
-
J Immunother Cancer
Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer. [Abstract]2022 Mar;10(3):e003667. PMID: 35288463 -
Cell Death Dis
2025 Jan 21;16(1):34. PMID: 39837817
Pembrolizumab purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jan 21;16(1):34. [Abstract]
Pembrolizumab (pembro) (5-10 µg/mL, 24 h). AMM16 cells were transfected with control siRNA (siRNA ctrl; left panels) or AR siRNA (siRNA AR; right panels) and treated with the indicated ICIs at 35 μg/ml. The red fluorescence from the propidium iodide (PI) and the green fluorescence from the acridin orange (AO) staining indicate dead and total cells, respectively.
-
Cell Death Dis
Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1-PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer. [Abstract]2021 May 9;12(5):465. PMID: 33967272
Pembrolizumab purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 May 9;12(5):465. [Abstract]
4T1 tumor-bearing mice treated with anti-PD-1 mAbs (Pembrolizumab, 10 mg/kg; i.p.; twice a week) or LY2940002 (25 mg/kg; i.p.; twice a week) were euthanized at Day21 and the tumor volume were measured. The results showed that the administration of anti-PD-1 mAbs (Pembrolizumab), LY294002, or their combination significantly inhibited tumor growth in tumor-bearing mice.
-
-
Cancer Immunol Immunother
Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer. [Abstract]2022 Jul;71(7):1645-1654. PMID: 34767045 -
Cell Oncol (Dordr)
Optimized patient-derived lung cancer organoids recapitulating the immune landscape for precision therapy evaluation. [Abstract]2026 Jan 6;49(1):15. PMID: 41493730 -
Int Immunopharmacol
The role and mechanism of PAK5 in the development and immunotherapy of oral squamous cell carcinoma. [Abstract]2025 Aug 27:164:115406. PMID: 40876424 -
Int J Cancer
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]2024 Jul 15;155(2):324-338. PMID: 38533706 -
ACS Appl Bio Mater
2020 Oct 19;3(10):7080-7086. PMID: 35019367
Pembrolizumab purchased from MedChemExpress. Usage Cited in: ACS Appl Bio Mater. 2020 Oct 19;3(10):7080-7086. [Abstract]
The immunofluorescence images of the tumor from the PBS- (A), random sequence- (B), anti-PD-1 antibody- (Pembrolizumab (5 mg/kg; s.c.; every other day for 16 days)) (C) and isotype antibody-treated group (D); The scale bar in the images is 50 µm.
-
J Biomed Inform
2023 Jun:142:104383. PMID: 37196989 -
Sci Rep
Pembrolizumab promotes degradation of cyclin dependent kinase 6 and suppresses ovarian cancer progression in vitro. [Abstract]2025 Jul 12;15(1):25283. PMID: 40652113 -
Biotechnol Bioeng
Elucidation of Proteoforms of Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2) Captured From a Monoclonal Antibody. [Abstract]2025 Nov 10. PMID: 41211761 -
Immunol Res
FOXP4-AS1 promotes CD8+ T cell exhaustion and esophageal cancer immune escape through USP10-stabilized PD-L1. [Abstract]2024 Aug;72(4):766-775. PMID: 38687433 -
Oral Dis
Effect of PTEN Overexpression Plus Anti-PD-1 on Immune Escape in Oral Squamous Cell Carcinoma. [Abstract]2025 Jul 20. PMID: 40684460 -
-
-
-
-
-
-
-
-
-
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93. [Content Brief]
[2]. Zhenglin Ou, et al. Pressure increases PD‑L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti‑ROR1 CAR T cell‑mediated cytotoxicity, Sci Rep [Content Brief]
[4]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)